Grand Pharmaceutical GroupCGPHF 87 Net Margin % is 1.16% as of Dec. 2025, which is 93% below its 10-year median of 17.66. GuruFocus rates CGPHF with a GF Score™ of 87/100. The stock has 6 warning signs investors should review. Among 956 Drug Manufacturers companies, Grand Pharmaceutical Group ranks better than 64.75% on this metric.
The historical rank and industry rank for Grand Pharmaceutical Group's Net Margin % or its related term are showing as below:
CGPHF'
s Net Margin % Range Over the Past 10 Years
Min: 7.28 Med: 17.66 Max: 28.22
Current: 10.1
CGPHF's Net Margin % is ranked better than 64.75% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs CGPHF: 10.10
Grand Pharmaceutical Group (OTCPK:CGPHF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Grand Pharmaceutical Group Net Margin % Related Terms
Grand Pharmaceutical Group Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Net Margin % distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Pharmaceutical Group (CGPHF) has a Net Margin % of 1.16% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Grand Pharmaceutical Group and its competitors. This is 93% below median its historical median of 17.66. Over the past decade, Grand Pharmaceutical Group's Net Margin % has ranged from 7.28 to 28.22. According to the industry distribution chart, Grand Pharmaceutical Group ranks #337 out of 956 companies in the Drug Manufacturers industry, placing it in the top 35.3%.
Is Grand Pharmaceutical Group's Net Margin % too high?
Grand Pharmaceutical Group's current Net Margin % of 1.16% is 93% below median its 10-year median of 17.66. Over the past 10 years, this metric has ranged from a low of 7.28 to a high of 28.22. The Drug Manufacturers industry median Net Margin % is 5.56. Grand Pharmaceutical Group's value of 1.16% is 79.1% below this industry median. Based on the distribution chart, Grand Pharmaceutical Group ranks #337 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grand Pharmaceutical Group has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #337 out of 956 companies for Net Margin %. This puts Grand Pharmaceutical Group in the upper half of its industry. The industry median Net Margin % is 5.56. Grand Pharmaceutical Group's value of 1.16% is 79.1% below this benchmark. Historically, Grand Pharmaceutical Group's own Net Margin % has ranged from 7.28 to 28.22 over the past decade. While the company's 10-year median is 17.66 vs. the industry median of 5.56, Grand Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current Net Margin % of 1.16% is 79.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current Net Margin % is 1.16%, which is 93% below median its own 10-year median of 17.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current Net Margin % of 1.16%. The current Net Margin % is 1.16%, which is 93% below median its 10-year median of 17.66 and 79.1% below the Drug Manufacturers industry median of 5.56. Grand Pharmaceutical Group's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current Net Margin % is 1.16% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGPHF has been successfully added to your 